1st Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for FERRING PHARMACEUTICALS INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit

Foreign entity interest: Ferring Holdings SA and Ferring BV listed on the registration under foreign entities have an interest in healthcare policy as the ultimate parent company.

LobbyistCovered position, as disclosed
BRANDT ANDERSON —
EMILY FELDER —
HAROLD HANCOCK —
MARK L. PRYOR New United States Senator
DAVID REID New None
EDWARD RANDALL ROYCE New Representative, U.S. House of Representatives
ADAM STEINMETZ —
DEEMA TARAZI —
JONATHAN TOWERS —

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Veterans VET

Issues related to veteran's care and veteran's reproductive care

Foreign entity interest: Ferring Holdings SA and Ferring BV listed on the registration under foreign entities have an interest in veteran's care.

LobbyistCovered position, as disclosed
JONATHAN TOWERS —

Trade (domestic/foreign) TRD

Issues related to pharmaceutical tariffs

Foreign entity interest: Ferring Holdings SA and Ferring BV listed on the registration under foreign entities have an interest in pharmaceutical tariffs.

LobbyistCovered position, as disclosed
AARON CUMMINGS —
EMILY FELDER —
JOSEPH BRADY HOWELL —
TIM SHADYAC —

Contacted: Bureau of Industry and Security (BIS); U.S. Trade Representative (USTR); SENATE; Commerce, Dept of (DOC); Executive Office of the President (EOP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.